Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389867 | 0.86 | TBK1 (0.46) | TBK1GPR119PIK3CAPRKDCSCN9A | |
| SCHEMBL5399443 | 0.78 | GPR119 (0.47) | GPR119USP30FAAHLIMK2KDM4E | |
| SCHEMBL391067 | 0.78 | GPR119 (0.47) | TBK1GPR119PIK3CAPRKDC | |
| SCHEMBL389112 | 0.78 | TBK1 (0.48) | TBK1GPR119PIK3CAPRKDCSCN9A | |
| SCHEMBL391649 | 0.77 | GPR119 (0.46) | TBK1GPR119PIK3CAPRKDCLIMK2 | |
| SCHEMBL4722370 | 0.75 | TBK1 (0.39) | TBK1GPR119 | |
| SCHEMBL5395249 | 0.75 | GPR119 (0.53) | GPR119FAAHLIMK2KDM4EPKM | |
| SCHEMBL387995 | 0.75 | GPR119 (0.47) | TBK1GPR119PIK3CAPRKDCLIMK2 | |
| SCHEMBL389718 | 0.74 | TBK1 (0.44) | TBK1GPR119PIK3CAPRKDCSCN9A | |
| SCHEMBL386784 | 0.74 | GPR119 (0.46) | TBK1GPR119PIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |